.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Find suppliers and generic API sources
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Express Scripts
Chubb
Fish and Richardson
Farmers Insurance
Citi
Moodys
Julphar
McKesson
Boehringer Ingelheim

Generated: June 26, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 090313

« Back to Dashboard
NDA 090313 describes SODIUM POLYSTYRENE SULFONATE, which is a drug marketed by Citrusphrma, Cmp Pharma Inc, Eci Pharms Llc, Invatech Pharma, Morton Grove, Belcher Pharms Llc, Epic Pharma Llc, West-ward Pharms Int, Roxane, Nuvo Pharm Inc, Wockhardt, and Paddock Llc, and is included in twelve NDAs. It is available from twelve suppliers. Additional details are available on the SODIUM POLYSTYRENE SULFONATE profile page.

The generic ingredient in SODIUM POLYSTYRENE SULFONATE is sodium polystyrene sulfonate. There are one thousand three hundred and seventy-nine drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the sodium polystyrene sulfonate profile page.

Summary for NDA: 090313

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Therapeutic Class:Antidotes, Deterrents, and Toxicologic Agents
Formulation / Manufacturing:see details

Suppliers and Packaging for NDA: 090313

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
SODIUM POLYSTYRENE SULFONATE
sodium polystyrene sulfonate
POWDER;ORAL, RECTAL 090313 ANDA Exact-Rx, Inc. 42808-500 42808-500-16 453.6 g in 1 JAR (42808-500-16)
SODIUM POLYSTYRENE SULFONATE
sodium polystyrene sulfonate
POWDER;ORAL, RECTAL 090313 ANDA ECI Pharmaceuticals, LLC 51293-831 51293-831-97 453.6 g in 1 JAR (51293-831-97)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:POWDER;ORAL, RECTALStrength453.6GM/BOT
Approval Date:Dec 21, 2011TE:AARLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

QuintilesIMS
Farmers Insurance
Teva
McKinsey
Harvard Business School
Accenture
Cipla
Moodys
US Army
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot